151 related articles for article (PubMed ID: 31766065)
1. PSMA-negative prostate cancer and the continued value of choline-PET/CT.
Alberts I; Sachpekidis C; Fech V; Rominger A; Afshar-Oromieh A
Nuklearmedizin; 2020 Feb; 59(1):33-34. PubMed ID: 31766065
[No Abstract] [Full Text] [Related]
2.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
3. Therapy assessment in prostate cancer using choline and PSMA PET/CT.
Ceci F; Herrmann K; Hadaschik B; Castellucci P; Fanti S
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):78-83. PubMed ID: 28540419
[TBL] [Abstract][Full Text] [Related]
4. PSMA PET/CT for staging and treatment of prostate cancer.
Hofman M
Clin Adv Hematol Oncol; 2019 Jul; 17(7):370-373. PubMed ID: 31449501
[No Abstract] [Full Text] [Related]
5. Molecular imaging using PSMA PET/CT versus multiparametric MRI for initial staging of prostate cancer: comparing apples with oranges?
Mottaghy FM; Heinzel A; Verburg FA
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1397-9. PubMed ID: 27118189
[No Abstract] [Full Text] [Related]
6. The future of choline PET in the era of prostate specific membrane antigen.
Evangelista L; Cuppari L; Zattoni F; Mansi L; Bombardieri E
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):19-28. PubMed ID: 29383928
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.
Bluemel C; Krebs M; Polat B; Linke F; Eiber M; Samnick S; Lapa C; Lassmann M; Riedmiller H; Czernin J; Rubello D; Bley T; Kropf S; Wester HJ; Buck AK; Herrmann K
Clin Nucl Med; 2016 Jul; 41(7):515-21. PubMed ID: 26975008
[TBL] [Abstract][Full Text] [Related]
8. The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer.
Aragon-Ching JB
Asian J Androl; 2021; 23(1):1-2. PubMed ID: 32719192
[No Abstract] [Full Text] [Related]
9. Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis.
Kim SJ; Lee SW; Ha HK
Urol Int; 2019; 102(1):27-36. PubMed ID: 30269140
[TBL] [Abstract][Full Text] [Related]
10. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
11. Effective Prostate-Specific Membrane Antigen-Based 18F-DCFPyL-Guided Cryoablation of a Single Positive Site in a Patient Believed to Be More Metastatic on 11C-Choline PET/CT.
Cornelis FH; Durack JC; Morris MJ; Scher HI; Solomon SB
Clin Nucl Med; 2017 Dec; 42(12):e516-e518. PubMed ID: 29099733
[TBL] [Abstract][Full Text] [Related]
12. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
[TBL] [Abstract][Full Text] [Related]
13. Advances in prostate-specific membrane antigen PET of prostate cancer.
Bouchelouche K; Choyke PL
Curr Opin Oncol; 2018 May; 30(3):189-196. PubMed ID: 29465429
[TBL] [Abstract][Full Text] [Related]
14. Correlation of PSMA-Targeted
Tosoian JJ; Gorin MA; Rowe SP; Andreas D; Szabo Z; Pienta KJ; Pomper MG; Lotan TL; Ross AE
Clin Genitourin Cancer; 2017 Feb; 15(1):e65-e68. PubMed ID: 27751686
[No Abstract] [Full Text] [Related]
15. Cold Kit for Prostate-Specific Membrane Antigen (PSMA) PET Imaging: Phase 1 Study of
Hofman MS; Eu P; Jackson P; Hong E; Binns D; Iravani A; Murphy D; Mitchell C; Siva S; Hicks RJ; Young JD; Blower PJ; Mullen GE
J Nucl Med; 2018 Apr; 59(4):625-631. PubMed ID: 28986512
[No Abstract] [Full Text] [Related]
16. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
17. Prostate-Specific Membrane Antigen PET/CT Combined with Sentinel Node Biopsy for Primary Lymph Node Staging in Prostate Cancer.
Hinsenveld FJ; Wit EMK; van Leeuwen PJ; Brouwer OR; Donswijk ML; Tillier CN; Vegt E; van Muilekom E; van Oosterom MN; van Leeuwen FWB; van der Poel HG
J Nucl Med; 2020 Apr; 61(4):540-545. PubMed ID: 31562222
[TBL] [Abstract][Full Text] [Related]
18. Incidentally Detected 18F-PSMA Uptake in Glomus Jugulare.
Zade A; Trivedi C; Ingule A; Jha S; Agrwal A
Clin Nucl Med; 2020 Aug; 45(8):e360-e362. PubMed ID: 32520502
[TBL] [Abstract][Full Text] [Related]
19.
Fendler WP; Eiber M; Beheshti M; Bomanji J; Ceci F; Cho S; Giesel F; Haberkorn U; Hope TA; Kopka K; Krause BJ; Mottaghy FM; Schöder H; Sunderland J; Wan S; Wester HJ; Fanti S; Herrmann K
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1014-1024. PubMed ID: 28283702
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls.
Hofman MS; Hicks RJ; Maurer T; Eiber M
Radiographics; 2018; 38(1):200-217. PubMed ID: 29320333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
